clinical trial · NCT02754726
Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
HonorHealth Research Institute·phase2·completed·n = 35
Untreated Metastatic Pancreatic Ductal AdenocarcinomaNivolumabAlbumin-bound paclitaxelParicalcitolCisplatinGemcitabine
brief summary
The purpose of this study is to find out if the study drugs nivolumab, albumin- bound paclitaxel, paricalcitol, cisplatin, and gemcitabine given together are safe and effective when combined to treat advanced pancreatic cancer.
started
Apr 1, 2016
primary completion
Apr 11, 2023
completion
Mar 22, 2024
last updated
Aug 27, 2025
official title
A Phase II Pilot Trial of Nivolumab + Albumin-Bound Paclitaxel + Paricalcitol + Cisplatin + Gemcitabine (NAPPCG) In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol